Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study

**Aim** To identify breast cancer subtypes likely to respond to primary systemic therapy (PST or neoadjuvant therapy) and to assess the accuracy of physical examination (PE) and breast ultrasonography (US) in evaluating and predicting residual size of breast carcinoma following PST.

**Methods** 116 patients who received at least two cycles of PST between 1998 and 2009 were selected from a prospectively collected clinical database. Radiological assessment was done by mammography and US. Prior to PST, tumors were subclassified according to core biopsy (NCB) and/or fine-needle aspiration-based immunohistochemical profiles of NCB. Pathological response rates were assessed following the surgeries by using Chevallier classification. Tumor measurements by PE and US were obtained before and after PST. Different clinical measurements were compared with histological findings. Disease-free survival (DFS) was assessed.

**Results** Pathological complete remission (pCR = Chevallier I/II) was observed in 25 patients (21.5%), 44% of whom had triple negative histology, 28% Her2 positive and 76% had high-grade tumor. Of 116 patients, 24 received taxane-based PST, 48 combined taxane + anthracycline treatment, 8 trastuzumab combinations, 21 anthracycline-based treatments, and 15 other treatments. In the taxane treated group, the pCR rate was 30%, in the taxane + anthracycline group 25%, in the anthracycline group 9.5%, and in trastuzumab group 37.5%. After PST, PE and US were both significantly associated with pathology ($P < 0.001$ and $P = 0.004$, respectively). Concerning OS, significant difference was observed between the Chevallier III and IV group ($P = 0.031$) in favor of Chevallier III group. In the pCR group, fewer events were observed during the follow-up period.

**Conclusions** Our results show that even limited, routinely used immunohistochemical profiling of tumors can predict the likelihood of pCR to PST: patients with triple negative and Her2-positive cancers are more likely to achieve pCR to PST. Also, PE is better correlated with pathological findings than US.

Gyöngyvér Szentmártoni¹, Anna-Mária Tőkés², Timea Tőkés¹, Krisztian Somlai³, Attila Marcell Szász², László Torgyik¹, Janina Kulka³, Magdolna Dank¹

¹Semmelweis University, Department of Clinical Oncology, Budapest, Hungary
²2nd Department of Pathology, Budapest, Hungary
³Surgical Division of St. Margit Hospital, Budapest, Hungary

Received: January 8, 2016
Accepted: March 24, 2016
Correspondence to:
Magdolna Dank
Semmelweis Univ. Dept. of Clinical Oncology
Tomo str. 25-29
Budapest: H-1083, Hungary
dank.oncology@gmail.com
There are many controversial data on the benefits and risks of primary systemic therapy (PST) of breast cancer. It is generally accepted that PST results in various clinical responses in 60%-90% of patients, while pathologic complete remission (pCR), the predictor of overall survival, occurs only in 3%-16% of patients (1-3).

Although the response rate of breast cancers to PST is a short-term marker, it has a long-term outcome and important influence on patients’ life. Therefore, it is important to identify new and reliable factors that may predict response to PST. Several studies have been conducted with the aim to identify predictive factors for pCR after administration of PST. Early identification of features that can predict pCR may allow a better selection of patients. However, there is no global consensus on the predictive factors. The role of hormone receptor status, tumor grade, and tumor cell proliferation has already been established (1-8). A large number of studies showed that women with luminal A type cancer (ER-positive/Her2-negative) were unlikely to achieve a pCR after optimal neoadjuvant chemotherapy (9,10). Based on this observation, some experts consider that patients with luminal A tumors are not eligible for preoperative chemotherapy (11).

Controversies exist in the assessment of the accuracy of physical examination, sonography, and mammography in predicting the residual size of breast tumors following PST (12,13). Physical examination is one of the accepted clinical standards in the evaluation of tumor size before, during, and after neoadjuvant chemotherapy, while pathological evaluation is the gold standard and the ultimate assessment modality of the residual tumor size after neoadjuvant chemotherapy (14,15). Ultrasound (US) is used primarily for diagnostic purposes – size and biopsy – and for wire localization. It is considered complementary to mammography and PE. The sensitivity and specificity of PE and US vary in different studies (1,12,16,17). Sperber et al correlated the findings of PE, US and mammography performed by the same oncologic and radiologic team in patients with locally advanced breast cancer or a tumor/breast tissue ratio that precludes breast-conserving surgery. They found that none of these methods adequately delineated the real extent of the disease in the breast and axillary lymph nodes (18). Peintinger et al calculated the agreement between the predicted and the pathologic responses and the predicted and pathologic tumor sizes by using PE, mammography, and US at diagnosis and before surgery in 162 breast cancer patients who received PST. They found that the overall agreement between predicted and pathologic responses was 53% for PE, 67% for mammography plus US, and 63% for PE plus mammography and US. The sensitivity of mammography and US in predicting pCR was 78.6%, the specificity was 92.5%, and the accuracy was 88.9. Agreement of residual tumor size in mammography and US with pathologic residual tumor size was moderate (18,19). In a recent study, the US estimated pathologic tumor size correctly in 63%, overestimated it in 20%, and underestimated it in 17% of 182 patients who underwent PST. However, US was as least as good as breast MRI (20).

Given the important role of the assessment of residual tumor size in determining the surgical procedure after neoadjuvant chemotherapy the aims of this study were:

1) to prospectively evaluate the accuracy of PE and US for clinical staging of primary breast cancer in women receiving neoadjuvant chemotherapy. Until rebiopsy after first cycle of therapy or novel molecular imaging methods will be available in the everyday practice, we need to establish which of the conventional evaluating methods has the highest predictive value for pCR;

2) to compare the results with pathologic measurement performed on surgical specimens;

3) to determine the breast cancer subgroups likely to respond to neoadjuvant chemotherapy;

4) to correlate the results of pathological response evaluation (ie, Chevallier classification) with the disease free survival (DFS).

METHODS

Patients

116 patients who received at least two cycles of PST between 1998 and 2009 were selected from a prospectively collected clinical database. Patients were not included in the study if there was evidence of inflammatory breast cancer, metastatic disease, previous hormonal therapy for breast cancer, and surgery and radiotherapy. Radiological assessment was done by mammography and US (PET/CT and MRI were only available in the second part of the analyzed period therefore not considered in this study). Tumor measurements by PE, and US were performed before and after PST. Prior to PST, tumors were subclassified according to core biopsy (NCB) and/or fine-needle aspiration-based immunohistochemical profiles of NCB. Pathologi-
Clinical response rates were assessed following the surgeries by using Chevallier classification. Different clinical measurements were compared with histological findings. Disease-free survival was assessed. Distant metastases were screened by chest x-ray, abdominal sonography, or by CT scan/PET CT.

Clinical assessment

Clinical measurements (physical examination and/or breast sonography) were performed before treatment, at every two or three cycles during therapy, and at the end of neoadjuvant treatment. The average number of treatment cycles was 5.6; the majority of patients underwent 6 cycles.

Data on the PE of the tumors were available in 108/116 patients and on US in 58/116 patients. Clinical palpation, ultrasonography, and treatment were performed by the same well trained team consisting of oncologists and radiologists at Semmelweis University. Regarding PE, palpation and caliper measurements were performed by the treating physician. Breast US was routinely performed before and after PST by the same experienced radiologist in our institute. Those US results that did not meet these criteria were excluded from the analysis. Patients’ demographics, tumor characteristics, and the largest diameter of the multidimensional tumor measurement obtained by physical examination and/or sonography were recorded. The findings were compared with pathological staging.

The clinical response to neoadjuvant chemotherapy was classified according to the Union for International Cancer Control (UICC) criteria (cCR – complete response; cPR – partial response; cSD – stable disease; and cPD – progressive disease) (21,22).

Pathological assessment

Histopathological diagnosis, hormone receptor status, and Her2/neu status were determined based on the core biopsy or fine-needle aspiration biopsy (FNAB) before neoadjuvant therapy. Estrogen (ER) and progesterone receptor (PR) status were determined by using 6F11 and the PR clone 312 (both from Novocastra Laboratories Ltd, Burlingame, CA, USA), respectively, and standard immunohistochemical methods. Tumors with >10% stained cells were considered to have positive receptor status. HER2/neu status was assessed by immunohistochemistry (HER2/neu CB11, Novocastra Laboratories Ltd). CB11 was scored by experienced pathologists according to approved guidelines (23).

In 23 cases, the fluorescence in situ hybridization (FISH) data were available. FISH was performed again in these cases by using a fluorescein-labeled HER2 probe (ERBB2, Her2/Neu, Kreatech Diagnostics, Amsterdam, The Netherlands) and automated technique (Ventana Medical Systems, Inc., Tucson, AZ, USA) (24-26).

Pathological response rates were assessed following surgical removal of tumors on hematoxylin and eosin stained slides. The pathological response to neoadjuvant chemotherapy was defined by using the Chevallier classification (I-IV) (class I – no residual carcinomas in breast or axillary nodes; class II – only in situ carcinoma remaining, nodes are negative; class III – invasive carcinoma with stromal fibrosis; and class IV – no or few modifications in the tumor), and class I and II is considered as pCR (27).

Statistics

Statistical analyses were performed using Statistica 64 v12 (Statsoft Inc., Tulsa, OK, USA) and SPSS 15.0 Family Pack (SPSS, Inc., Chicago, IL, USA). For categorical variables, numbers were allocated for every investigated category. For continuous variables, the results are shown as means ± standard deviations, and median with interquartile range (IQR). Categorical variables were compared using χ² test or Fisher exact method, depending on the number of the variables in the contingency tables. Disease-free and overall survival was estimated from the date of pathological diagnosis (core-biopsy sampling) to the date of last follow-up or death using the Kaplan-Meier survival probability estimator. Log-rank test was used to evaluate the effect of different variables on DFS and OS. All statistical tests
were two-sided. Differences were considered to be statistically significant at $P < 0.05$.

**RESULTS**

We assessed the clinicopathological characteristics of the included 116 patients (Table 1). The patients' median age at the time of diagnosis was 49.94 years (IQR 38-59). The median pretreatment tumor size assessed by PE was 40 mm (IQR 30-50) and if assessed by breast US it was median 27 mm (IQR 22-36 mm). According to the preoperative data the vast majority of patients had invasive ductal carcinoma (83.62%), while the others had invasive carcinoma not otherwise characterized, and lobular, mixed, and other types of carcinoma, each amounting to <10%. Most patients had T2 tumors (56.9%), 16.4% had T3, 12% had T4 tumors, and only 9.5% had T1 tumors.

Among 116 patients there were 67 node-positive cases (57.8%). With regard to hormone receptor status, 52.6% of the tumors were ER positive and 34.5% were PR positive.

Of 116 patients, 24 received taxane-based PST, 48 combined taxane + anthracycline treatment, 8 trastuzumab combinations, 21 anthracycline-based treatments, and 15 other treatments. In the taxane treated group, the pCR rate was 30%, in the taxane + anthracycline group 25%, in the anthracycline group 9.5%, and in trastuzumab group 37.5%.

Upon pathological review of tumor and nodal status, pathological complete or near-complete remission (pCR = Chevallier I and II) was observed in 25 of 116 cases (21.5%), 44% of whom had triple negative histology and 76% had high-grade tumor. According to the preoperative characteristics of the 25 tumors achieving pCR, 11 of the cases were triple negative, 7 were luminal B, and 7 were Her2 positive. Only 10 luminal-A patients were enrolled in this study, and all of these patients failed to achieve pCR. The same was true for the majority of luminal B tumors (35/42, 83.4%).

Univariate regression analysis was used to estimate the effects of clinical and pathological characteristics on response to neoadjuvant chemotherapy. Negative ER and PR status and Her2 positivity were the factors associated with an increased percentage of pCR (Table 2).

The menopausal status was not associated with the likelihood of achieving pCR. We did not find any significant correlation (Chi square: 4.76, df = 2, $P = 0.093$). But in the pCR group patients’ mean age was significantly lower than in the non-pCR group (44.4 ± 12.3 vs 50.8 ± 11.8, $P = 0.017$).

PE and US measurements were also compared with the residual pathologic tumor size. According to the PE

### TABLE 1. Pretreatment patient and tumor characteristics of 116 patients*

| Characteristic       | n   | %   |
|----------------------|-----|-----|
| **Age**              |     |     |
| premenopausal        | 47  | 40.9|
| perimenopausal       | 11  | 9.5 |
| postmenopausal       | 57  | 49.6|
| **Clinical T stage**|     |     |
| T1                   | 11  | 9.5 |
| T2                   | 66  | 56.9|
| T3                   | 19  | 16.4|
| T4                   | 14  | 12.1|
| no data              | 6   | 5.1 |
| **Clinical N stage**|     |     |
| node positive        | 67  | 57.8|
| node negative        | 35  | 30.1|
| no data              | 14  | 12.1|
| **Histology**        |     |     |
| IDC                  | 97  | 83.6|
| ILC                  | 3   | 2.6 |
| other                | 16  | 13.8|
| **ER**               |     |     |
| positive             | 61  | 52.6|
| negative             | 42  | 36.2|
| no data              | 13  | 11.2|
| **PR**               |     |     |
| positive             | 40  | 34.5|
| negative             | 61  | 52.6|
| no data              | 15  | 12.9|
| **Her2/neu**         |     |     |
| positive             | 32  | 27.6|
| negative             | 73  | 62.9|
| no data              | 11  | 9.5 |
| **Neoadjuvant regimen** |     |     |
| taxane               | 24  | 20.7|
| anthracycline        | 21  | 18.1|
| T+A                  | 48  | 41.3|
| trastuzumab          | 8   | 6.9 |
| other                | 15  | 13  |

*P – tumor, N – node, IDC – invasive ductal carcinoma, ILC – invasive lobular carcinoma, ER – estrogen receptor, PR – progesterone receptor, Her2 – human epidermal growth factor receptor 2, T+A – taxane + anthracycline.

**TABLE 2. Univariate predictors of pCR to neoadjuvant chemotherapy for breast cancer**

| Characteristics | P   |
|-----------------|-----|
| PR negativity   | 0.004|
| HER2 positivity | 0.027|
| ER negativity   | 0.002|
| Therapy         | NS  |

*pCR – pathological complete response, ER – estrogen receptor, PR – progesterone receptor, Her2 – human epidermal growth factor receptor 2, NS – not significant.
data and UICC evaluation criteria, 27.6% of the patients achieved a clinical CR. However, the pathological complete response rate was lower: 21.5%. According to the results obtained by US, the clinical CR rate was 15.5% but we had the US measurement data for only 58 patients (Tables 3 and 4).

**TABLE 3. The results of physical examination compared to pathological response after primary systemic therapy (n = 105 patients, unknown PE data in 11 cases)**

| Chevallier I+II | PE - CR | PE - PR | PE - SD |
|----------------|---------|---------|---------|
| 16 (55.2%)     | 9 (15.3%) | 0 (0%)  |
| 12 (41.4%)     | 38 (64.4%) | 8 (47.1%) |
| 1 (3.4%)       | 12 (20.3%) | 9 (52.9%) |
| Total          | 29 (100%)  | 59 (100%) | 17 (100%) |

*PE – physical examination, CR – complete response, PR – partial response, SD – stable disease.

**TABLE 4. The results of breast ultrasonography compared to pathological response after primary systemic therapy (n = 58 patients, US restaging was incomplete in 58 patients)**

| Chevallier I+II | US - CR | US - PR | US - SD | US - PD |
|----------------|---------|---------|---------|---------|
| 5 (55.6%)      | 9 (24.3%) | 0 (0%)  | 0       |
| 4 (44.4%)      | 25 (67.6%) | 6 (17.7%) | 0       |
| 0 (%)          | 3 (8.1%)  | 3 (27.3%) | 1 (100%) |
| Total          | 9 (100%)  | 37 (100%) | 11 (100%) | 1 (100%) |

*US – ultrasound, CR – complete response, PR – partial response, SD – stable disease, PD – progressive disease.

Of the 25 patients who achieved a complete pathological response, 9 were clinically described as partial clinical responders; the remaining were described as complete responders using PE. Based on the results of US for clinical evaluation of the 14 patients with available data from this group 5 achieved a complete pathological response and 9 achieved partial response (Tables 3 and 4). After neoadjuvant chemotherapy, both PE- and US-measured clinical remission associated significantly with pathological remission, (P<0.001 and P=0.004, respectively).

We further analyzed whether in pCR cases US added an additional value to PE evaluation. We found that in cases when PE correctly identified pCR, only 50% of US examinations showed complete remission – the false positivity rate was high. In those pCR cases when PE was false positive, only one US examination contradicted the result of PE by showing clinical complete remission. Thus, US did not add any additional diagnostic value to PE.

The median follow-up was 56.1 months (IQR 36.3-77.1 months). Concerning DFS, pCR was not associated with better outcome (P=0.804), however the number of patients with early disease progression in the pCR group was lower than in the non-pCR group (3 vs 15), but the difference was not significant (Figure 1). We also did not find significantly better OS in the pCR group (P=0.237), but it should be noted that in the pCR group there were fewer events (CH III) during the follow-up period. Nonetheless, when we compared the four Chevallier subgroups regarding OS, we still not find differences (P=0.079) however with subgroup analysis between the Chevallier III and IV groups we detected significant differences in the OS time (P=0.031) (Figure 2).

**FIGURE 1. Disease free survival of pathological complete response (pCR) group compared to non pCR group, not significant (P=0.804).**

**FIGURE 2. Overall survival in the four different Chevallier groups, not significant (P=0.07). Significant differences we found between the Chevallier III and IV groups (P=0.031).**
DISCUSSION

In this study, we evaluated the accuracy of PE and US for clinical staging of primary breast cancer in women receiving PST, by correlating the results with pathologic measurement performed on surgical specimens and to determine the breast carcinoma subgroups likely to respond to PST.

The assessment of residual tumor size is important in planning the initial treatment course and also in monitoring disease response to the treatment. There are controversies regarding the reliability of the methods used to evaluate the size of residual breast carcinomas. Physical examination, US, mammography, and MRI have all been used to assess tumor size before, during, and after neoadjuvant chemotherapy in the everyday practice. A recent study by our team assessed the tumor response by our novel, breast cancer specific FDG-PET/CT criteria, which accurately differentiated pCR from non-pCR patients (28). However, the availability and costs of novel methods indicate that we should evaluate and investigate more classical techniques of tumor measurement. PE, US, and mammography are frequently used techniques for tumor measurements, but high false positivity rates (20%, 65%, and 46%, respectively) and notable false negativity rates (57%, 10%, and 20%, respectively) were published. Earlier studies suggested that PE was the best noninvasive predictor of the real size of breast cancer, but MRI can give the best correlation with pathology (12,29-31). When comparing the methods used for clinical assessment with final pathological findings the published results are heterogeneous, but still showing high correlation for PE and for US (32). We found that both PE and US were associated significantly with the final histology, however, PE showed slightly better results than US. The limitation of PE is that tumors smaller than 2 cm sometimes are not detectable. In contrast, if a large tumor shows considerable decrease in size by clinical examination, there could also be remaining small tumor foci with minimal residual disease. These small foci, scattered in a relative large area, could be defined as residual tumor or stable disease by the final pathological assessment. This result implies that the clinical diagnosis of cCR does not necessarily reflect the pathologic CR. It also means that the level of inaccuracy must be taken into consideration when assessing patient’s suitability for breast conserving surgery or for alternative chemotherapy. Even if cCR is achieved, it is possible that viable tumor tissue is still present at the primary site in some cases. It is generally accepted that three types of information can be used to estimate the probability of pCR: the tumor response after two courses of treatment, molecular markers, and clinical phenotype including hormone receptor status, tumor subtype, grade, and age (1,22). Several trials indicated that the absence of any response after the first two cycles was predictive for low probability of pCR even after completing chemotherapy (13,33). The majority of researchers agree that patients with ER negative and HER2-amplified breast cancer are more likely to achieve pCR (1,7,10,34,35). In our study, of the 25 tumors achieving pCR, 11 were triple negative, 7 were luminal B, and 7 were Her2 positive. This result is consistent with recently published data of other groups (4,7,19,36). Tan et al using a multivariate analysis have found that negative hormone receptor status, N0 nodal status before therapy, and HER2 amplifications are independent predictors of pCR (22).

The association between pCR and DFS or OS is always questionable. Large clinical trials of neoadjuvant therapy have demonstrated that patients with pCR have better DFS and OS compared with those with residual tumors (36,37). Fisher et al (38) concluded that long term DFS and OS were similar after neoadjuvant and adjuvant chemotherapies when similar chemotherapy regimens were used. We found that pCR was not associated with significantly better outcome, however, it should be highlighted that in the pCR group the number of early disease progression was significantly lower than in the non-pCR group (3 vs 15). Tan et al (22) by analyzing 518 breast cancer patients receiving neoadjuvant therapy also concluded that OS was not significantly different in patients with pCR and with residual disease. It needs to be mentioned that the follow-up period in the mentioned study (22) was rather short (<4 years). Similar results were reported by Jung et al (39) and the recently published meta-regression analysis by Berruti et al (40).

In conclusion, we found that both PE and US measured clinical remission was associated significantly with final pathology results, but PE was slightly more accurate than US. Serial US did not provide additional useful information in the majority of cases, but provided useful additional information in questionable cases. Imaging techniques like mammography, US, and MRI can help in cases when PE fails to identify the tumor. We determined the breast cancer subgroups likely to respond to primary systemic therapy and we found that patients with ER and PR negative, Her2-positive cancers were more likely to achieve pCR. Finally, pCR was not associated with significantly better DFS. Concerning OS, significant difference was observed between the Chevallier III and IV group and fewer events were observed in the pCR group.
The most important limitation of our study was the small number of events during the follow-up period; therefore we were not able to analyze OS in different tumor subgroups comparatively. Additionally, should be highlighted that the number of US examination was lower than expected due to strict inclusion criteria.

PE and US are the most generally used diagnostic methods worldwide in the prediction of residual tumor after neoadjuvant chemotherapy. We conclude that PE should be the basic method for evaluation of breast tumors during PST in classical candidates with locally advanced, T2 or larger, node positive tumors.

Acknowledgment We thank Cedars Sinai Medical Center’s International Research and Innovation in Medicine Program, the Association for Regional Cooperation in the Fields of Health, Science and Technology (RECOOP HST Association) for their support.

Funding None.

Ethical approval for the study was obtained from the Semmelweis University Institutional Review Board. (No. 76/2007).

Declaration of authorship G Sz, LT, and KS carried out the collection of clinical data. LT and GSz performed cTNM classification. TT, AMT, and AMSz collected pathological data and performed the Chevallier and Sataloff scoring. These were overseen by JK. TT and GSz performed the statistical analyses. G Sz drafted the manuscript. MD conceived the study, participated in its design and coordination, and helped to complete the final manuscript. All authors read, corrected, and approved the final manuscript.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request) and declare: no support from any organization that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Pusztai L. Preoperative systemic chemotherapy and pathologic assessment of response. Pathol Oncol Res. 2008;14:169-71. Medline:18553157 doi:10.1196/12253-008-9070-8
2 Teshome M, Hunt KK. Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23:505-23. Medline:24882348 doi:10.1016/j.soc.2014.03.006
3 Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91:2012-7. Medline:15558072 doi:10.1038/sj.bjc.6602235
4 Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-34. Medline:17438091 doi:10.1158/1078-0432.CCR-06-1109
5 Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009;27:220-6. Medline:19047281
6 Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, et al. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015;153:417-23. Medline:26272743 doi:10.1007/s10549-015-3533-x
7 Liedtke C, Mазouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-81. Medline:18250347 doi:10.1200/JCO.2007.14.4147
8 Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol. 2007;60:1300-6. Medline:17630399 doi:10.1136/jcp.2006.045377
9 Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10:6622-8. Medline:15475452 doi:10.1158/1078-0432.CCR-04-0380
10 Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-85. Medline:16115903 doi:10.1158/1078-0432.CCR-04-2421
11 Andre F, Delaloge S. Neoadjuvant chemotherapy for breast cancers: current recommendations and future directions. Eur J Cancer. 2009;45 Suppl 1:3368-70. Medline:19775634 doi:10.1016/S0959-8049(09)70052-8
12 Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Budzar AU, Mirza AN, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243:257-64. Medline:16432360 doi:10.1097/01.sla.0000197714.14318.6f
13 von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008;10:R30. Medline:18380893 doi:10.1186/bcr1989
14 Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: eight years experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93-100. Medline:9440728
15 Kaufmann M, Minckwitz G, Mammounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an International Consensus Conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508-16. Medline:22193884 doi:10.1245/sj01434-011-2108-2
16 Penault-Llorca F, Abrial C, Raoelilis I, Caye A, Mouret-Reynier MA, Leherteur M, et al. Comparison of the prognostic significance of Chevalier and Slattof’s pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008;39:1221-8. Medline:18547616 doi:10.1016/j.
humpath.2007.11.019

17 Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang H. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer. 2011;115:194-202. Medline:19156919 doi:10.1002/cncr.214154

18 Sperber F, Weinstein Y, Sarid D, Ben Yosef R, Shalon A, Yaal-Hahoshen N Preoperative clinical, mammographic and sono graphic assessment of neoadjuvant chemotherapy response in breast cancer. Isr Med Assoc J. 2006;8:342-6. Medline:16805235

19 Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006;13:1443-9. Medline:17028770 doi:10.1245/s10434-006-9086-9

20 Vriens BE, de Vries B, Lobbes MB, van Gastel SM, van den Berkmoortel FW, Smilde TJ, et al. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Eur J Cancer. 2016;52:67-76. Medline:26650831 doi:10.1016/j.ejca.2015.10.010

21 Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segallot A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1997;75:292-8. Medline:856236 doi:10.1038/bjc.1977.42

22 Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Ann J Surg. 2009;198:520-5. Medline:19800460 doi:10.1016/j.amjsurg.2009.06.004

23 Hammad J, Lewis M, Phillips C, Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol. 2003;34:1043-7. Medline:14608539 doi:10.1053/s0046-8177(03)00409-X

24 Bankfalvi A, Giuffre G, Ofner D, Diallo R, Poremba C, Buchwalow IB, et al. Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis. Int J Oncol. 2003;23:1285-92. Medline:14532967

25 Luftner D, Henschke P, Kafka A, Anagnostopoulos I, Wiechen K, Geppert R, et al. Discordant results obtained for different methods of HER-2/neu testing in breast cancer—a question of standardization, automation and timing. Int J Biol Markers. 2004;19:1-13. Medline:15077921

26 Goldhirsh A, Winer EP, Coates AS, Gelber D, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert Consensus on the Primary Therapy of early Breast Cancer 2013. Ann Oncol. 2013;24:2206-23. Medline:23919790 doi:10.1093/annonc/mdt303

27 Chevalier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Ann J Clin Oncol. 1993;16:223-8. Medline:8338056 doi:10.1097/00000421-199306000-00006

28 Török T, Szentmártoni G, Gogyőr M, Lengyel Z, Györke T, et al. Response evaluation after primary systemic therapy of HER2 positive breast cancer- an observational cross-sectional study. Croat Med J. 2015;56:128-38. Medline:25891872 doi:10.3325/cmj.2015.56.128

29 Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1993;3:1565-9. Medline:918544

30 Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol. 2005;184:868-877. Medline:15728611 doi:10.2214/ajr.184.3.01840868

31 An YY, Kim SH, Kang BJ, Lee AW. Treatment response evaluation of breast cancer after neoadjuvant chemotherapy and usefulness of the imaging parameters of MRI and PET/CT. J Korean Med Sci. 2015;30:808-15. Medline:26028936 doi:10.3346/jkms.2015.30.6.808

32 Gawne-Cain ML, Smith E, Darby M, Given-Wilson R. The use of ultrasound for monitoring breast tumour response to pre-adjuvant therapy. Clin Radiol. 1995;50:681-6. Medline:7586959 doi:10.1016/0009-9260(95)83312-4

33 Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-66. Medline:11896092 doi:10.1200/JCO.20.6.1456

34 Hirata T, Shimizu C, Yonemori K, Harikawa A, Kouno T, Tamura K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 2009;101:1529-36. Medline:19809429 doi:10.1038/sj.bjc.6605360

35 de Ronde JJ, Hannemann M, Hallwerk H, Mulder L, Staver ME, Vrancken Peeters MJ, et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat. 2010;119:119-26. Medline:19669409 doi:10.1007/s10549-009-0499-6

36 von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Faschinger PA, et al. Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796-804. Medline:22508812 doi:10.1200/JCO.2011.38.8595

37 Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85. Medline:18258986

38 Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher R, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-85. Medline:9704717

39 Jung SY, Kim SK, Nam BH, Min SY, Lee SJ, Park C, et al. Prognostic Impact of (18F) FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17:247-53. Medline:19777177 doi:10.1245/s10434-009-0710-3

40 Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol. 2014;32:3883-91. Medline:25349292 doi:10.1200/JCO.2014.55.2836